Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
about
Role of telavancin in treatment of skin and skin structure infectionsTelavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infectionsIntrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.Synthetic lipopeptides: a novel class of anti-infectives.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.Management of methicillin-resistant Staphylococcus aureus bacteremia.A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.Are glycopeptides still appropriate and convenient for empiric use?Vancomycin resistance: are there better glycopeptides coming?Newer developments in the treatment of Gram-positive infections.Peptidoglycan biosynthesis machinery: a rich source of drug targets.Medical management of diabetic foot infections.Update on carbohydrate-containing antibacterial agents.Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.
P2860
Q34620329-F3B1D4DE-B6FE-4938-B3EB-C44467231594Q35026607-0568868F-16AE-413F-A9F7-D4C1FB2431FBQ36422696-E13B3AFC-D326-4FBC-9FF2-7BF82C0FCD6AQ36904839-1ADC9956-52A8-4636-8528-C810EAEBDA99Q37077627-0AC37A0C-0FB1-4C20-B67B-C33183041B67Q37156709-E731584D-FAFE-4BF1-9623-753B1F7D1E44Q37252733-62399788-AD19-4D52-8ECC-B25D062E30CAQ37331777-731C9EA3-BBE4-4DF7-95AA-ACB9BA370C3DQ37333194-C739EEEC-D9DF-4F72-9F12-7445435763CCQ37340562-84A11DCA-F593-461C-AB85-B6EA2E9A0207Q37636151-C6155D10-B951-451F-A26D-A709346B3F30Q37810971-C04E6714-F69A-492A-A5D8-39FBEF9D2ACDQ37995865-F469D75C-4322-486A-AE6F-236E12CE35BAQ38089193-1483DB2B-1E71-4539-85B8-097B7CD47E79Q39686295-0D47ED96-0E2E-4373-B82D-E2953AF29194Q39816590-2ABDCDF2-A4F4-43E0-87A1-0AF7F6833653Q41028154-E797CE09-0C95-40BC-88BE-A1CACDAC26F9Q42788454-B4C0D625-BD19-488A-99A0-3A224D2545F2Q46489824-3524D081-A30A-4BEA-9CE8-A257D5591061
P2860
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
@ast
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
@en
type
label
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
@ast
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
@en
prefLabel
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
@ast
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
@en
P2093
P2860
P1476
Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
@en
P2093
David P Nicolau
Joseph L Kuti
Somvadee Laohavaleeson
P2860
P304
P356
10.1517/13543784.16.3.347
P407
P577
2007-03-01T00:00:00Z